Medtronic has quietly built a solid three year share price record, while rolling out new medical technologies that keep it in the headlines. The open question for anyone looking at the stock today is whether the current market value lines up with the cash flows the business is expected to generate.
- With a 41.4% return over the past three years, the stock has already paid investors well, which raises the bar for what its future cash flows need to support.
- Recognition for devices like the Stealth AXiS surgical system and Corsano wearable, plus heavy R&D and robotics investment, can shape expectations for how quickly Medtronic turns that spending into durable cash generation.
- Prefer to judge Medtronic on earnings? See what Medtronic's 21.7x P/E says about the price.
The issue now is whether the current share price around US$92.77 is adequately backed by the cash flows implied by Medtronic's intrinsic value estimate under its Discounted Cash Flow (DCF) approach.
If you want more ideas built around medical technology and robotics, a focused screener of 92 robotics and automation stocks is a useful next step in your research.
Does Medtronic Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here takes Medtronic’s projected free cash flows and discounts them back to today. On the latest figures, the business generated about $6.1b of free cash flow over the past twelve months, with analyst and internal estimates pointing to higher annual cash generation heading into the early 2030s before easing into slower growth in the second stage of the model.
Those assumptions, combined with the current share price of $92.77, explain why the DCF output suggests Medtronic’s estimated intrinsic value is meaningfully above where the stock trades. Recognition for products like the Stealth AXiS surgical system and Corsano wearable on TIME’s Best Inventions of 2026 list helps show why analysts are comfortable modelling continued free cash flow strength, even as heavy R&D and robotics spending affects nearer term margins. Find out what Medtronic could be worth using our Discounted Cash Flow (DCF) estimate.
The Medtronic Narrative: What Would Justify Today's Price?
Medtronic’s valuation puzzle only really comes into focus once you see the Simply Wall St Narratives that sit behind it, because these lay out the specific paths for growth, profitability and earnings that would need to play out for the shares to be worth materially more or meaningfully less than today’s price, and they live on Simply Wall St’s Community page. Each one links its number to a clear view on how Medtronic’s expansion, margins and risk profile might evolve, which you can track against future results and new information.
Community views on Medtronic split between those who see more upside in the current setup and others who treat the stock as roughly fairly priced.
Bull case: 12% undervalued
"Medtronic's push into connected ecosystems across spine and soft tissue surgery, including the AiBLE spine platform and the Hugo and Sentire robotic systems, is gaining traction through rising procedure volumes and low current penetration levels…"
Discover why this Narrative puts Medtronic at 12% undervalued.
Bear case: roughly fairly valued
"Medtronic plc recently acquired Scientia Vascular to expand its neurovascular technology portfolio…"
Explore why this Narrative puts Medtronic at roughly fairly valued.
The Medtronic share price is only one piece of the decision
Cash flows and valuation models say a lot about Medtronic, yet the people steering the business and how their pay is structured can quietly shape outcomes in ways the numbers alone never show. See who runs Medtronic and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com